Rucaparib,Nivolumab
BMS,clovis oncology
['rucaparib', 'ovarian']
athena trial published at simultaneously with #asco22:
stage 3/4 ovarian cancer, postcht maintenance rucaparib vs. placebo hrd + cohort pfs; 28.7 vs 11.3 mos, hr:0.47 hrd- cohort pfs; 12.1 vs 9.1 mos, hr:0.65 
Medical Oncologist